Immunotherapy Using Immunogenic Mimotopes Selected by Phage Display plus Amphotericin B Inducing a Therapeutic Response in Mice Infected with <i>Leishmania amazonensis</i>
<i>Leishmania amazonensis</i> can cause cutaneous and visceral clinical manifestations of leishmaniasis in infected hosts. Once the treatment against disease is toxic, presents high cost, and/or there is the emergence of parasite-resistant strains, alternative means through which to cont...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Pathogens |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-0817/12/2/314 |
| _version_ | 1827756040408530944 |
|---|---|
| author | Tauane G. Soyer Fernanda F. Ramos Isabela A. G. Pereira Daniela P. Lage Raquel S. Bandeira Marcelo M. de Jesus Guilherme P. Costa Amanda S. Machado Camila S. Freitas Danniele L. Vale Vívian T. Martins Alexsandro S. Galdino Miguel A. Chávez-Fumagalli Daniel Menezes-Souza Mariana C. Duarte Bruno M. Roatt Eduardo A. F. Coelho Grasiele S. V. Tavares |
| author_facet | Tauane G. Soyer Fernanda F. Ramos Isabela A. G. Pereira Daniela P. Lage Raquel S. Bandeira Marcelo M. de Jesus Guilherme P. Costa Amanda S. Machado Camila S. Freitas Danniele L. Vale Vívian T. Martins Alexsandro S. Galdino Miguel A. Chávez-Fumagalli Daniel Menezes-Souza Mariana C. Duarte Bruno M. Roatt Eduardo A. F. Coelho Grasiele S. V. Tavares |
| author_sort | Tauane G. Soyer |
| collection | DOAJ |
| description | <i>Leishmania amazonensis</i> can cause cutaneous and visceral clinical manifestations of leishmaniasis in infected hosts. Once the treatment against disease is toxic, presents high cost, and/or there is the emergence of parasite-resistant strains, alternative means through which to control the disease must be developed. In this context, immunotherapeutics combining known drugs with immunogens could be applied to control infections and allow hosts to recover from the disease. In this study, immunotherapeutics protocols associating mimotopes selected by phage display and amphotericin B (AmpB) were evaluated in <i>L. amazonensis</i>-infected mice. Immunogens, A4 and A8 phages, were administered alone or associated with AmpB. Other animals received saline, AmpB, a wild-type phage (WTP), or WTP/AmpB as controls. Evaluations performed one and thirty days after the application of immunotherapeutics showed that the A4/AmpB and A8/AmpB combinations induced the most polarized Th1-type immune responses, which reflected in significant reductions in the lesion’s average diameter and in the parasite load in the infected tissue and distinct organs of the animals. In addition, the combination also reduced the drug toxicity, as compared to values found using it alone. In this context, preliminary data presented here suggest the potential to associate A4 and A8 phages with AmpB to be applied in future studies for treatment against leishmaniasis. |
| first_indexed | 2024-03-11T08:17:34Z |
| format | Article |
| id | doaj.art-0e72ffa459d24221bdbdd07350467a1d |
| institution | Directory Open Access Journal |
| issn | 2076-0817 |
| language | English |
| last_indexed | 2024-03-11T08:17:34Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pathogens |
| spelling | doaj.art-0e72ffa459d24221bdbdd07350467a1d2023-11-16T22:34:56ZengMDPI AGPathogens2076-08172023-02-0112231410.3390/pathogens12020314Immunotherapy Using Immunogenic Mimotopes Selected by Phage Display plus Amphotericin B Inducing a Therapeutic Response in Mice Infected with <i>Leishmania amazonensis</i>Tauane G. Soyer0Fernanda F. Ramos1Isabela A. G. Pereira2Daniela P. Lage3Raquel S. Bandeira4Marcelo M. de Jesus5Guilherme P. Costa6Amanda S. Machado7Camila S. Freitas8Danniele L. Vale9Vívian T. Martins10Alexsandro S. Galdino11Miguel A. Chávez-Fumagalli12Daniel Menezes-Souza13Mariana C. Duarte14Bruno M. Roatt15Eduardo A. F. Coelho16Grasiele S. V. Tavares17Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, BrazilPrograma de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, BrazilPrograma de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, BrazilPrograma de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, BrazilPrograma de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, BrazilPrograma de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, BrazilLaboratório de Imunopatologia, Núcleo de Pesquisas em Ciências Biológicas/NUPEB, Departamento de Ciências Biológicas, Insituto de Ciências Exatas e Biológicas, Universidade Federal de Ouro Preto, Ouro Preto 35400-000, BrazilPrograma de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, BrazilPrograma de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, BrazilPrograma de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, BrazilPrograma de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, BrazilLaboratório de Biotecnologia de Microrganismos, Universidade Federal de São João Del-Rei, Divinópolis 35501-296, BrazilComputational Biology and Chemistry Research Group, Vicerrectorado de Investigación, Universidad Católica de Santa María, Urb. San José S/N, Umacollo, Arequipa 04000, PeruPrograma de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, BrazilPrograma de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, BrazilLaboratório de Imunopatologia, Núcleo de Pesquisas em Ciências Biológicas/NUPEB, Departamento de Ciências Biológicas, Insituto de Ciências Exatas e Biológicas, Universidade Federal de Ouro Preto, Ouro Preto 35400-000, BrazilPrograma de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, BrazilPrograma de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil<i>Leishmania amazonensis</i> can cause cutaneous and visceral clinical manifestations of leishmaniasis in infected hosts. Once the treatment against disease is toxic, presents high cost, and/or there is the emergence of parasite-resistant strains, alternative means through which to control the disease must be developed. In this context, immunotherapeutics combining known drugs with immunogens could be applied to control infections and allow hosts to recover from the disease. In this study, immunotherapeutics protocols associating mimotopes selected by phage display and amphotericin B (AmpB) were evaluated in <i>L. amazonensis</i>-infected mice. Immunogens, A4 and A8 phages, were administered alone or associated with AmpB. Other animals received saline, AmpB, a wild-type phage (WTP), or WTP/AmpB as controls. Evaluations performed one and thirty days after the application of immunotherapeutics showed that the A4/AmpB and A8/AmpB combinations induced the most polarized Th1-type immune responses, which reflected in significant reductions in the lesion’s average diameter and in the parasite load in the infected tissue and distinct organs of the animals. In addition, the combination also reduced the drug toxicity, as compared to values found using it alone. In this context, preliminary data presented here suggest the potential to associate A4 and A8 phages with AmpB to be applied in future studies for treatment against leishmaniasis.https://www.mdpi.com/2076-0817/12/2/314phage displaymimotopesimmunotherapeuticstegumentary leishmaniasisimmune responseamphotericin B |
| spellingShingle | Tauane G. Soyer Fernanda F. Ramos Isabela A. G. Pereira Daniela P. Lage Raquel S. Bandeira Marcelo M. de Jesus Guilherme P. Costa Amanda S. Machado Camila S. Freitas Danniele L. Vale Vívian T. Martins Alexsandro S. Galdino Miguel A. Chávez-Fumagalli Daniel Menezes-Souza Mariana C. Duarte Bruno M. Roatt Eduardo A. F. Coelho Grasiele S. V. Tavares Immunotherapy Using Immunogenic Mimotopes Selected by Phage Display plus Amphotericin B Inducing a Therapeutic Response in Mice Infected with <i>Leishmania amazonensis</i> Pathogens phage display mimotopes immunotherapeutics tegumentary leishmaniasis immune response amphotericin B |
| title | Immunotherapy Using Immunogenic Mimotopes Selected by Phage Display plus Amphotericin B Inducing a Therapeutic Response in Mice Infected with <i>Leishmania amazonensis</i> |
| title_full | Immunotherapy Using Immunogenic Mimotopes Selected by Phage Display plus Amphotericin B Inducing a Therapeutic Response in Mice Infected with <i>Leishmania amazonensis</i> |
| title_fullStr | Immunotherapy Using Immunogenic Mimotopes Selected by Phage Display plus Amphotericin B Inducing a Therapeutic Response in Mice Infected with <i>Leishmania amazonensis</i> |
| title_full_unstemmed | Immunotherapy Using Immunogenic Mimotopes Selected by Phage Display plus Amphotericin B Inducing a Therapeutic Response in Mice Infected with <i>Leishmania amazonensis</i> |
| title_short | Immunotherapy Using Immunogenic Mimotopes Selected by Phage Display plus Amphotericin B Inducing a Therapeutic Response in Mice Infected with <i>Leishmania amazonensis</i> |
| title_sort | immunotherapy using immunogenic mimotopes selected by phage display plus amphotericin b inducing a therapeutic response in mice infected with i leishmania amazonensis i |
| topic | phage display mimotopes immunotherapeutics tegumentary leishmaniasis immune response amphotericin B |
| url | https://www.mdpi.com/2076-0817/12/2/314 |
| work_keys_str_mv | AT tauanegsoyer immunotherapyusingimmunogenicmimotopesselectedbyphagedisplayplusamphotericinbinducingatherapeuticresponseinmiceinfectedwithileishmaniaamazonensisi AT fernandaframos immunotherapyusingimmunogenicmimotopesselectedbyphagedisplayplusamphotericinbinducingatherapeuticresponseinmiceinfectedwithileishmaniaamazonensisi AT isabelaagpereira immunotherapyusingimmunogenicmimotopesselectedbyphagedisplayplusamphotericinbinducingatherapeuticresponseinmiceinfectedwithileishmaniaamazonensisi AT danielaplage immunotherapyusingimmunogenicmimotopesselectedbyphagedisplayplusamphotericinbinducingatherapeuticresponseinmiceinfectedwithileishmaniaamazonensisi AT raquelsbandeira immunotherapyusingimmunogenicmimotopesselectedbyphagedisplayplusamphotericinbinducingatherapeuticresponseinmiceinfectedwithileishmaniaamazonensisi AT marcelomdejesus immunotherapyusingimmunogenicmimotopesselectedbyphagedisplayplusamphotericinbinducingatherapeuticresponseinmiceinfectedwithileishmaniaamazonensisi AT guilhermepcosta immunotherapyusingimmunogenicmimotopesselectedbyphagedisplayplusamphotericinbinducingatherapeuticresponseinmiceinfectedwithileishmaniaamazonensisi AT amandasmachado immunotherapyusingimmunogenicmimotopesselectedbyphagedisplayplusamphotericinbinducingatherapeuticresponseinmiceinfectedwithileishmaniaamazonensisi AT camilasfreitas immunotherapyusingimmunogenicmimotopesselectedbyphagedisplayplusamphotericinbinducingatherapeuticresponseinmiceinfectedwithileishmaniaamazonensisi AT dannielelvale immunotherapyusingimmunogenicmimotopesselectedbyphagedisplayplusamphotericinbinducingatherapeuticresponseinmiceinfectedwithileishmaniaamazonensisi AT viviantmartins immunotherapyusingimmunogenicmimotopesselectedbyphagedisplayplusamphotericinbinducingatherapeuticresponseinmiceinfectedwithileishmaniaamazonensisi AT alexsandrosgaldino immunotherapyusingimmunogenicmimotopesselectedbyphagedisplayplusamphotericinbinducingatherapeuticresponseinmiceinfectedwithileishmaniaamazonensisi AT miguelachavezfumagalli immunotherapyusingimmunogenicmimotopesselectedbyphagedisplayplusamphotericinbinducingatherapeuticresponseinmiceinfectedwithileishmaniaamazonensisi AT danielmenezessouza immunotherapyusingimmunogenicmimotopesselectedbyphagedisplayplusamphotericinbinducingatherapeuticresponseinmiceinfectedwithileishmaniaamazonensisi AT marianacduarte immunotherapyusingimmunogenicmimotopesselectedbyphagedisplayplusamphotericinbinducingatherapeuticresponseinmiceinfectedwithileishmaniaamazonensisi AT brunomroatt immunotherapyusingimmunogenicmimotopesselectedbyphagedisplayplusamphotericinbinducingatherapeuticresponseinmiceinfectedwithileishmaniaamazonensisi AT eduardoafcoelho immunotherapyusingimmunogenicmimotopesselectedbyphagedisplayplusamphotericinbinducingatherapeuticresponseinmiceinfectedwithileishmaniaamazonensisi AT grasielesvtavares immunotherapyusingimmunogenicmimotopesselectedbyphagedisplayplusamphotericinbinducingatherapeuticresponseinmiceinfectedwithileishmaniaamazonensisi |